Novartis’ Strategic Adoption of Snowflake Data Cloud Transforms Data Management and Drives Breakthroughs in Drug Discovery

The multinational corporation involved in the pharmaceutical industry, Novartis, transitioned its drug discovery approach with Snowflake Data Cloud. Founded in 2012, Snowflake revolutionized the way large datasets are integrated, analyzed, and securely shared, helping break data silos and advance research. The gain of faster access to insights consolidated the Novartis researchers into shared work areas, with the improvement of the query performance. Thus, Snowflake provided significant scalability to handle the volume of data required, and the platform also had strong compliance characteristics to meet the stringent regulatory requirements of the industry. Among the benefits realized from the transition, top on the list were; a decrease in data silos, enhanced query performance, an increase in usage of data and probably the greatest, a reduction in costs. The Snowflake case describes how Novartis, a pharmaceutical firm, leveraged cloud-based data platforms to unlock the power of data and drive innovation in drug development.